PLoS ONE (Jan 2012)

Valproate alters dopamine signaling in association with induction of Par-4 protein expression.

  • Saebom Lee,
  • Jaehoon Jeong,
  • Young-Un Park,
  • Yongdo Kwak,
  • Seol Ae Lee,
  • Haeryun Lee,
  • Hyeon Son,
  • Sang Ki Park

DOI
https://doi.org/10.1371/journal.pone.0045618
Journal volume & issue
Vol. 7, no. 9
p. e45618

Abstract

Read online

Chromatin remodeling through histone modifications has emerged as a key mechanism in the pathophysiology of psychiatric disorders. Valproate (VPA), a first-line medication for bipolar disorder, is known to have histone deacetylase (HDAC) inhibitor activity, but the relationship between its efficacy as a mood stabilizer and HDAC inhibitory activity is unclear. Here we provide evidence that prostate apoptosis response-4 (Par-4), an intracellular binding partner of dopamine D2 receptors (DRD2), plays a role in mediating the effectiveness of VPA. We found that chronic VPA treatment enhanced the expression of Par-4 in cultured neurons and adult mouse brains. This Par-4 induction phenomenon occurred at the transcriptional level and was correlated with an increase in histone H3 and H4 acetylation of the Par-4 promoter regions. Furthermore, chronic VPA treatment potentiated the suppression of the cAMP signaling cascade upon dopamine stimulation, which was blocked by sulpiride treatment. These results indicate that VPA potentiates DRD2 activity by enhancing Par-4 expression via a chromatin remodeling mechanism.